Aprogen Biologics Balance Sheet Health
Financial Health criteria checks 4/6
Aprogen Biologics has a total shareholder equity of ₩435.6B and total debt of ₩106.9B, which brings its debt-to-equity ratio to 24.5%. Its total assets and total liabilities are ₩631.3B and ₩195.6B respectively.
Key information
24.5%
Debt to equity ratio
₩106.88b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩60.88b |
| Equity | ₩435.62b |
| Total liabilities | ₩195.65b |
| Total assets | ₩631.27b |
Recent financial health updates
Recent updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24Financial Position Analysis
Short Term Liabilities: A003060's short term assets (₩151.3B) exceed its short term liabilities (₩132.0B).
Long Term Liabilities: A003060's short term assets (₩151.3B) exceed its long term liabilities (₩63.7B).
Debt to Equity History and Analysis
Debt Level: A003060's net debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: A003060's debt to equity ratio has increased from 2.8% to 24.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A003060 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A003060 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 46.5% each year